Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Schmid, Peter, Adams, Sylvia, Rugo, Hope S., Schneeweiss, Andreas, Barrios, Carlos H., Iwata, Hiroji, Diéras, Véronique, Hegg, Roberto, Im, Seock-Ah, Shaw Wright, Gail, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y., Funke, Roel, Husain, Amreen, Winer, Eric P., Loi, Sherene, Emens, Leisha A.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1809615

Cited by (1,010)

Items 601–700 of 1,010

CACA Guidelines for Holistic Integrative Management of Breast Cancer
Jiong Wu, Daiming Fan, Zhimin Shao, Binghe Xu, Guosheng Ren, Zefei Jiang, Yongsheng Wang, Feng Jin, Jin Zhang, Qingyuan Zhang et al. · 2022 · Holistic Integrative Oncology
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, Georgia, Tzilas, Vasilios, Kotteas, Elias, Syrigos, Konstantinos, Bouros, Demosthenes · 2020 · Respiration
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
Joe Poh-Sheng Yeong, Tira J. Tan, Zi Long Chow, Qing Cheng, Bernett Teck Kwong Lee, Amanda Oon Lim Seet, Johnathan Xiande Lim, Jeffrey Chun Tatt Lim, Clara Chong Hui Ong, Aye Aye Thike et al. · 2020 · Journal of Clinical Pathology
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
William Jacot, Evelyne Lopez‐Crapez, Caroline Mollévi, Florence Boissière‐Michot, Joëlle Simony-Lafontaine, Alexandre Ho-Pun-Cheung, Elodie Chartron, Charles G. Theillet, Antoinette Lemoine, Raphaël Saffroy et al. · 2020 · Cancers
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu et al. · 2020 · Breast Cancer Research
Heavy‐Atom‐Modulated Supramolecular Assembly Increases Antitumor Potency against Malignant Breast Tumors via Tunable Cooperativity
Zhengqing Guo, Hui He, Yi Zhang, Jiaming Rao, Tao Yang, Ting Li, Lu Wang, Mengke Shi, Mengya Wang, Shihong Qiu et al. · 2020 · Advanced Materials
Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression
Jenny Stenström, Ingrid A. Hedenfalk, Catharina Hagerling · 2021 · Breast Cancer Research
Immunotherapy Treatment for Triple Negative Breast Cancer
Elizabeth Rapp Berger, Tristen S. Park, Angeleke Saridakis, Mehra A. Golshan, Rachel A. Greenup, Nita Ahuja · 2021 · Pharmaceuticals
A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype
Zihao Chen, Maoli Wang, Rudy Leon De Wilde, Ruifa Feng, Mingqiang Su, Luz Angela Torres-de la Roche, Wenjie Shi · 2021 · Frontiers in Immunology
Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer
M. Nunez Abad, Silvia Calabuig Fariñas, M. Lobo de Mena, Susana Torres‐Martínez, Clara García González, José Ángel García, Vega Iranzo, Carlos Camps · 2022 · Cancers
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer
Iván Pérez-Núñez, Catalina Rozalén, José Ángel Palomeque, Irene Sangrador, Mariona Dalmau, Laura Comerma, Anna Hernández‐Prat, David Casadevall, Sílvia Menéndez, Daniel Dan Liu et al. · 2022 · Nature Cancer
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
Caroline Bergenfelz, Anna Roxå, Meliha Mehmeti, Karin Leandersson, Anna-Maria Larsson · 2020 · Cancer Immunology Immunotherapy
microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy
Ranjana Kumari Kanchan, Jawed Akhtar Siddiqui, Sidharth Mahapatra, Surinder K. Batra, Mohd Wasim Nasser · 2020 · Molecular Cancer
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Connie Kang, Yahiya Y. Syed · 2020 · Drugs
Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1
Hsuan‐Chen Liu, Dixita Ishani Viswanath, Federica Pesaresi, Yitian Xu, Licheng Zhang, Nicola Di Trani, Jesus Paez‐Mayorga, Nathanael Hernandez, Yu Wang, Donald R. Erm et al. · 2020 · International Journal of Radiation Oncology*Biology*Physics
Bioactive nanotherapeutic trends to combat triple negative breast cancer
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali Mohan Yallapu · 2021 · Bioactive Materials
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
Sandra van Wilpe, Sofie H. Tolmeijer, Rutger H.T. Koornstra, I. Jolanda M. de Vries, Winald R. Gerritsen, Marjolijn J. L. Ligtenberg, Niven Mehra · 2021 · Cancers
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Carrie Wynn, Shou‐Ching Tang · 2022 · Cancer and Metastasis Reviews
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer
Swarnima Singh, Nigel Lee, Diego A. Pedroza, Igor Bado, Clark Hamor, Licheng Zhang, Sergio Aguirre, Jingyuan Hu, Yichao Shen, Yitian Xu et al. · 2022 · Cancer Research
Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review
Ahmed Ismail, Hesham A. El‐Mahdy, Ahmed I. Abulsoud, Al-Aliaa M. Sallam, Mahmoud Gomaa Eldeib, Elsayed G.E. Elsakka, Mohamed Bakr Zaki, Ahmed Soliman Doghish · 2022 · International Journal of Biological Macromolecules
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
María del Mar Noblejas‐López, Cristina Nieto‐Jiménez, Sara Morcillo-García, Javier Pérez‐Peña, Miriam Nuncia‐Cantarero, Fernando Andrés Pretel, Eva María Galán‐Moya, Eitan Amir, Atanasio Pandiella, Balázs Győrffy et al. · 2019 · OncoImmunology
Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC)
Elizabeth F. Blackley, Sherene Loi · 2019 · The Breast
Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
Vito Amodio, Gianluca Mauri, Nicole Megan Reilly, Andrea Sartore Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano · 2021 · Cancers
The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Yun Chen, Yunjun Xiao, Yihang Pan, Peng Li · 2023 · British Journal of Cancer
Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy
Yue Wang, Shikun Zhou, Yan Wang, Zi-Dong Lu, Yue Zhang, Cong‐Fei Xu, Jun Wang · 2023 · Nature Communications
Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
Veerle C. M. Geurts, Marleen Kok · 2023 · Current Treatment Options in Oncology
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Diana C. Márquez‐Garbán, Gang Deng, Begonya Comin-Anduix, Alejandro J. Garcia, Yanpeng Xing, Hsiao‐Wang Chen, Gardenia C. Cheung-Lau, Nalo M. Hamilton, Michael E. Jung, Richard J. Pietras · 2019 · The Journal of Steroid Biochemistry and Molecular Biology
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Di Zhang, Paige Baldwin, Ana S. Leal, Sarah Carapellucci, Srinivas Sridhar, Karen T. Liby · 2019 · Theranostics
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab
Baxi, Vipul, Lee, George, Duan, Chunzhe, Pandya, Dimple, Cohen, Daniel N., Edwards, Robin, Chang, Han, Li, Jun, Elliott, Hunter, Pokkalla, Harsha et al. · 2022 · Modern Pathology
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
Hsiang‐Fong Kao, Pei‐Jen Lou · 2019 · Head & Neck
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
Athanasios Mavratzas, Julia Seitz, Katharina Smetanay, Andreas Schneeweiß, Dirk Jäger, Carlo Fremd · 2019 · Future Oncology
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Weiqi Wang, Yilan Jin, Xiao Liu, Fangmin Chen, Xiaohua Zheng, Tianqing Liu, Yumin Yang, Haijun Yu · 2021 · Advanced Functional Materials
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer
Kyung‐min Lee, Chang-Ching A. Lin, Alberto Servetto, Joonbeom Bae, Vishal Kandagatla, Dan Ye, Gun Min Kim, Dhivya R. Sudhan, Saurabh Mendiratta, Paula I. González Ericsson et al. · 2022 · Cancer Immunology Research
Quercetin Encapsulated in Folic Acid-Modified Liposomes is Therapeutic Against Osteosarcoma by Non-Covalent Binding to the Jh2 Domain of Jak2 Via the Jak2-Stat3-Pdl1
Doudou Jing, Wei Wu, Xuanzuo Chen, Hongwei Xiao, Zhenghao Zhang, Fengxia Chen, Zhicai Zhang, Jianxiang Liu, Zengwu Shao, Feifei Pu · 2022 · Pharmacological Research
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
Xiaoxiao Wang, L. Collet, Mattia Rediti, Véronique Debien, Alex De Caluwé, David Venet, Emanuela Romano, Françoise Rothé, Christos P. Sotiriou, Laurence Buisseret · 2023 · Journal of Clinical Medicine
Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy
Qiuxia Li, Xing Liu, Chunmei Yan, Bolin Zhao, Yuxin Zhao, Lu Yang, Mingyi Shi, Hua Yu, Xiaofang Li, Kaipei Luo · 2023 · Small
High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
Jaeyun Jung, You Jeong Heo, Sehhoon Park · 2023 · Journal for ImmunoTherapy of Cancer
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response
Guillaume P. Andrieu, Jordan S. Shafran, Charlotte L. Smith, Anna C. Belkina, Allison N. Casey, Naser Jafari, Gerald V. Denis · 2019 · Cancer Letters
Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer
Bum‐Sup Jang, Wonsik Han, In Ah Kim · 2019 · Radiotherapy and Oncology
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
Chiun‐Sheng Huang, Alice Lin-Tsing Yu, Ling‐Ming Tseng, Louis W.C. Chow, Ming‐Feng Hou, Sara Alsterlind Hurvitz, Richard B. Schwab, James Lee Murray, Hsien‐Kun Chang, Hong‐Tai Chang et al. · 2020 · Journal for ImmunoTherapy of Cancer
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression
Pengfei Xu, Wei Xiong, Yun Lin, Liping Fan, Hongchao Pan, Yaochen Li · 2021 · Cell Death and Disease
APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
Ashley V. DiMarco, Xiaodi Qin, Brock J. McKinney, Nina Marie G. Garcia, Sarah C. Van Alsten, Elizabeth A. Mendes, Jeremy Meyer Force, Brent Allen Hanks, Melissa A. Troester, Kouros Owzar et al. · 2021 · Cancer Immunology Research
Retracted: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity
Claire Vennin, Chiara Maria Cattaneo, Leontien Bosch, Serena Vegna, Xuhui Ma, Hugo G.J. Damstra, Moreno Martinovic, Efi Tsouri, Mila Ilić, Leyla Azarang et al. · 2023 · Cancer Cell · Retracted
Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Yiwen Zheng, Shujin Li, Hongchao Tang, Xuli Meng, Qinghui Zheng · 2023 · Frontiers in Immunology
Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer
Oluwatoyosi Adewunmi, Yichao Shen, Xiang H.-F. Zhang, Jeffrey M. Rosen · 2023 · Cancer Immunology Research
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari et al. · 2023 · Cancer Treatment Reviews
Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis
Meghana Kesireddy, Lina Elsayed, Valerie Shostrom, Priyal Agarwal, Samia Asif, Amulya Yellala, Jairam Krishnamurthy · 2024 · Cancers
Cyclometalated iridium(III) complex based on isoquinoline alkaloid synergistically elicits the ICD response and IDO inhibition via autophagy-dependent ferroptosis
Lu Yuan, Shanshan Wang, Mengya Li, Rong Liu, Meng-Fan Zhu, Liang-Mei Yang, Feng-Yang Wang, Ke-Bin Huang, Hong Liang · 2024 · Acta Pharmaceutica Sinica B
Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment
Stefano Tamburin, Susanna B. Park, Paola Alberti, Chiara Demichelis, Angelo E. Schenone, Andreas A. Argyriou · 2019 · Journal of the Peripheral Nervous System
Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype
Claire Deligne, Devadarssen Murdamoothoo, Anís N. Gammage, Martha Gschwandtner, William Erne, Thomas Loustau, Anna M. Marzeda, Raphaël Carapito, Nicodème Paul, Inés Velázquez-Quesada et al. · 2020 · Cancer Immunology Research
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
Débora De Melo Gagliato, Antonio Carlos Buzaid, José Manuel Pérez-García, Javier Cortés · 2020 · BioDrugs
Immunotherapy Approaches for Breast Cancer Patients in 2023
Leisha A. Emens, Sherene Loi · 2023 · Cold Spring Harbor Perspectives in Medicine
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+triple negative breast cancer cells
Nishant Mohan, Salman B. Hosain, Jun Wei Zhao, Yi Shen, Xiao Ling Luo, Jiangsong Jiang, Yukinori Endo, Wen Jin Wu · 2019 · OncoImmunology
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
John M. Seligson, Alexandra M. Patron, Michael J. Berger, Robert Donald Harvey, Nathan David Seligson · 2020 · Annals of Pharmacotherapy
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Ye Hu, Jiyue Gao, Meiling Wang, Man Li · 2021 · Cancer Management and Research
Extracellular vesicle–based drug delivery in cancer immunotherapy
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee · 2023 · Drug Delivery and Translational Research
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis
Yixian Wang, Zhan Xu, Kuan‐Lin Wu, Liqun Yu, Chenhang Wang, Haoxue Ding, Yang Gao, Han Sun, Yi-Hsuan Wu, Meng Xia et al. · 2024 · Proceedings of the National Academy of Sciences
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
Cathalijne Post, Anneke M. Westermann, Tjalling Bosse, Carien L. Creutzberg, Judith R. Kroep · 2020 · Critical Reviews in Oncology/Hematology
Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence
Corinna Slawinski, Jorge Barriuso, Hui Guo, Andrew G. Renehan · 2020 · Clinical Oncology
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
Shen Lin, Shaohong Luo, Lixian Zhong, Shubin Lai, Dayong Zeng, Xin Rao, Pinfang Huang, Xiuhua Weng · 2020 · International Journal of Clinical Pharmacy
Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1 -Mutant Breast Cancer
Michelle M. Williams, Nicole S. Spoelstra, Spencer Arnesen, Kathleen I. O’Neill, Jessica L. Christenson, Jordan M. Reese, Kathleen C. Torkko, Andrew E. Goodspeed, Emmanuel Rosas, Toru Hanamura et al. · 2020 · Cancer Research
PD-1/PD-L1 expression in pancreatic cancer and its implication in novel therapies
Adrian Mucileanu, Romeo Ioan Chira, Petru Adrian Mircea · 2021 · Medicine and Pharmacy Reports
Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer
Arushi Jaiswal, Kiichi Murakami, Andrew Elia, Yukiko Shibahara, Susan J. Done, Stephen A. Wood, Nicholas J. Donato, Pamela S. Ohashi, Michael Reedijk · 2021 · Proceedings of the National Academy of Sciences
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Selina K. Wong, Caroline A. Nebhan, Douglas Buckner Johnson · 2021 · Frontiers in Immunology
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
Foluso Olabisi Ademuyiwa, Feng Gao, Cherease Street, Ina Chen, DW Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, Elizabeth Claire Dees, Cesar Augusto Santa-Maria et al. · 2022 · npj Breast Cancer
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
Rebecca Alexandra Dent, Fabrice André, Anthony Gonçalvès, Miguel Martín, P. Schmid, F. Schütz, Sherko Kümmel, Sandra M. Swain, A. Bilici, Delphine Loirat et al. · 2024 · Annals of Oncology
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
Akihito Kawazoe, Kensei Yamaguchi, Hisateru Yasui, Yuji Negoro, Mizutomo Azuma, Kenji Amagai, Hiroki Hara, Hideo Baba, Masahiro Tsuda, Hisashi Hosaka et al. · 2020 · European Journal of Cancer
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease
Parvez Κhan, Jawed Akhtar Siddiqui, Shailendra Kumar Maurya, Imayavaramban Lakshmanan, Maneesh Jain, Apar Kishor Ganti, Ravi Salgia, Surinder K. Batra, Mohd Wasim Nasser · 2020 · Seminars in Cancer Biology
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Jason Schick, Raquel P. Ritchie, Carolina Baraldi A. Restini · 2021 · Breast Cancer Basic and Clinical Research
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Burak Yasin Aktaş, Hakan Taban, Sercan Aksoy · 2019 · New England Journal of Medicine
The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke)
Barca, Cristina, Foray, Claudia, Hermann, Sven, Herrlinger, Ulrich, Remory, Isabel, Laoui, Damya, Schäfers, Michael, Grauer, Oliver M., Zinnhardt, Bastian, Jacobs, Andreas H. · 2021 · Frontiers in Immunology
Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer
Yun Liu, Nasha Qiu, Limei Shen, Qi Liu, Jing Zhang, Yung‐Yi Cheng, Kuo‐Hsiung Lee, Leaf Huang · 2020 · Journal of Controlled Release
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Patrick J. Roberts, Vishnu Muthuraj Kumarasamy, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen · 2020 · Molecular Cancer Therapeutics
Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers
Jun Zhang, Zhen-Ru Wu, Xin Zhang, Si-Yun Liu, Jian Zhao, Fang Yuan, Yu-Jun Shi, B. Song · 2020 · ESMO Open
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
Jue Zhu, Lifeng Yan, Qiming Wang · 2021 · Journal of Ovarian Research
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
François Bertucci, Laurys Boudin, Pascal Finetti, Christophe Van Berckelaer, Peter A. van Dam, Luc Yves Dirix, Patrice Viens, Anthony Gonçalvès, Naoto Tada Ueno, Steven Van Laere et al. · 2021 · OncoImmunology
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
Fokhrul M. Hossain, Samarpan Majumder, Justin David, Lucio Miele · 2021 · Cancers
Immune response and inflammation in cancer health disparities
Maeve Bailey‐Whyte, Brittany Lord, Stefan Ambs · 2021 · Trends in cancer
Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC)
Damiano Cosimo Rigiracciolo, Nijiro Nohata, Rosamaria Lappano, Francesca Cirillo, Marianna Talia, Sendi Rafael Adame-Garcia, Nadia Arang, Simone Lubrano, Ernestina Marianna De Francesco, Antonino Belfiore et al. · 2022 · Journal of Experimental & Clinical Cancer Research
CD39 + tissue-resident memory CD8 + T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
Yong Joon Lee, Jee Ye Kim, Seung Hyuck Jeon, Heejin Nam, Jae Hyung Jung, Minwoo Jeon, Eui-Soon Kim, Soong June Bae, Juneyoung Ahn, Tae-Kyung Yoo et al. · 2022 · Science Immunology
mRNA-Based Therapeutics in Cancer Treatment
Han Sun, Yu Zhang, Ge Wang, Wen Yang, Yingjie Xu · 2023 · Pharmaceutics
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors
Giovanna Garufi, Antonella Palazzo, Ida Paris, Armando Orlandi, Alessandra Cassano, Giampaolo Tortora, Giovanni Scambia, Emilio Bria, Luisa Carbognin · 2020 · Expert Opinion on Pharmacotherapy
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
Brendan L. Mangan, Renee K. McAlister, Justin Micah Balko, Douglas Buckner Johnson, Javid J. Moslehi, Andrew Gibson, Elizabeth Jane Phillips · 2020 · British Journal of Clinical Pharmacology
Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple‐Negative Subtype of Breast Cancer Patients
Masanori Oshi, Stephanie Newman, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe · 2020 · Journal of Immunology Research
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Jennifer A. Weiss, Ashley Elizabeth Glode, Wells A. Messersmith, Jennifer Robinson Diamond · 2019 · Expert Review of Anticancer Therapy
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
Jodi M. Carter, Mei‐Yin C. Polley, Roberto Antonio Leon-Ferre, Jason P. Sinnwell, Kevin J. Thompson, Xue Wang, Yaohua Ma, David Zahrieh, Jennifer M. Kachergus, Malvika H. Solanki et al. · 2021 · Clinical Cancer Research
Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy
Yingli Wang, Jiang Yu, Dan Li, Liwen Zhao, Bingjun Sun, Jiamei Wang, Zhenjie Wang, Shuang Ying Zhou, Menglin Wang, Yinxian Yang et al. · 2021 · Journal of Controlled Release
The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors
Hamidreza Zalpoor, Fatemeh Aziziyan, Mahsa Liaghat, Maryam Bakhtiyari, Abdullatif Akbari, Mohsen Nabi‐Afjadi, Razieh Forghaniesfidvajani, Nima Rezaei · 2022 · Cell Communication and Signaling
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes
Nancy Tray, Jessica Taff, Baljit Singh, James H. Suh, Nhu Ngo, Maryann J. Kwa, Andrea B. Troxel, Young Kwang Chae, Razelle Kurzrock, Sandip Pravin Patel et al. · 2018 · The Breast
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model
Hanwen Wang, Oleg Milberg, Imke Heleen Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin K. Roskos, Cesar Augusto Santa-Maria, Aleksander S. Popel · 2019 · Royal Society Open Science
XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients
Esraa A. Salama, Reda E. Adbeltawab, Hend Mohamed El Tayebi · 2020 · Frontiers in Oncology
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
Hsing‐Ju Wu, Pei‐Yi Chu · 2021 · International Journal of Molecular Sciences
The Multifaceted Role of Regulatory T Cells in Breast Cancer
Kos, Kevin, de Visser, Karin E. · 2021 · Annual Review of Cancer Biology
Not all cancers are created equal: Tissue specificity in cancer genes and pathways
Joy J. Bianchi, Xin Zhao, Joseph C. Mays, Teresa Davoli · 2020 · Current Opinion in Cell Biology
Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple‐negative breast cancer
Shaoquan Zheng, Yutian Zou, Xinhua Xie, Jie‐Ying Liang, Anli Yang, Kai Yu, Jian Wang, Hailin Tang, Xiaoming Xie · 2020 · International Journal of Cancer
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Margaret L. Axelrod, Mellissa J. Nixon, Paula I. González Ericsson, Riley E. Bergman, Mark A. Pilkinton, Wyatt J. McDonnell, Violeta M. Sanchez, Susan R. Opalenik, Sherene Loi, Jing Zhou et al. · 2020 · Clinical Cancer Research
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
Elizabeth P. Darga, Emily M. Dolce, Fang Fang, KM Kidwell, Christina L. Gersch, Steven Kregel, Dafydd G. Thomas, Anoop Gill, Martha E. Brown, Steven C Gross et al. · 2021 · PLoS ONE
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Lawrence H. Fong, Michael J. Morris, Oliver A. Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Shivaram Alva, Leonard Joseph Appleman, Winston W. Tan, Ulka N. Vaishampayan, Raphaelle Porcu et al. · 2021 · Clinical Cancer Research
THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple‐Negative Breast Cancer
Xupeng Bai, Jie Ni, Julia Beretov, Shanping Wang, Xingli Dong, Peter Graham, Yong Li · 2021 · Advanced Science
Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy
Fotios Mpekris, Chrysovalantis Voutouri, Myrofora Panagi, James W. Baish, Rakesh K. Jain, Triantafyllos Stylianopoulos · 2022 · Journal of Controlled Release